Novartis meningitis vax promising in PhIII

Novartis' meningitis B vaccine, 4CMenB, has turned in promising late-stage data with "an acceptable" safety profile. After testing the drug in more than 3,600 infants, Novartis reported that its researchers tracked a "robust" immune response. A European app is expected by the end of this year. Story

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.